JPRN-jRCT2080220811
Unknown
Phase 2
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant Glioma
ConditionsMalignant glioma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Malignant glioma
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Enrollment
- 31
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \>\= 20 years
- •\-Histologically confirmed malignant glioma
- •\-All patients must have received prior temozolomide and prior radiation therapy for malignant glioma.
- •\-No evidence of recent hemorrhage on baseline MRI of the brain.
- •\-Karnofsky Performance Status \>\= 70%
Exclusion Criteria
- •\-The patient has received more than two regimens for malignant glioma.
- •\-History of hemoptysis(\>\=Grade2\) within 1 month before randomization.
- •\-Serious non\-healing wound or untreated bone fracture.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaCTIS2023-505698-34-00Merck Sharp & Dohme LLC102
Active, not recruiting
Phase 1
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma without any prior systemic treatmentMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-004490-52-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.110
Active, not recruiting
Phase 2
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinomaJPRN-jRCT2061210033Hoki Toshifumi6
Active, not recruiting
Phase 1
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaEUCTR2020-004490-52-PLMerck Sharp & Dohme LLC110
Completed
Phase 2
The safety of Cpn10 in patients with multiple sclerosisMultiple SclerosisNeurological - Multiple sclerosisACTRN12606000037505CBio Limited50